title: ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S.
abstract: Recent decades have seen a growth in treatments for attention deficit hyperactivity disorder (ADHD) including many branded and generic drugs. In the early 2000's, new drug entry dramatically altered market shares. We estimate a demand system for ADHD drugs and assess the welfare impact of new drugs. We find that entry induced large welfare gains by reducing prices of substitute drugs, and by providing alternative delivery mechanisms for existing molecules. Our results suggest that the success of follow-on patented drugs may come from unanticipated innovations like delivery mechanisms, a factor ignored by proposals to retard new follow-on drug approvals.
authors.affiliation: School of Economics and Centre for Competition Policy, University of East Anglia Norwich, Norfolk, NR4 7TJ, England.
authors.forename: Farasat A S
authors.initials: FA
authors.lastname: Bokhari
authors.affiliation: Department of Economics, Florida State University Tallahassee, Florida, 32306, U.S.A.
authors.forename: Gary M
authors.initials: GM
authors.lastname: Fournier
references.citation: Med Care. 2001 Dec;39(12):1293-304
references.pmid: 11717571
references.citation: Rand J Econ. 1997 Fall;28(3):426-46
references.pmid: 11794359
references.citation: N Engl J Med. 2007 Aug 16;357(7):673-81
references.pmid: 17699817
references.citation: Clin Ther. 2003 Dec;25(12):3147-61; discussion 3144-6
references.pmid: 14749153
references.citation: N Engl J Med. 2007 Nov 15;357(20):1993-6
references.pmid: 18003956
references.citation: Health Aff (Millwood). 2007 May-Jun;26(3):790-9
references.pmid: 17485758
references.citation: Pharmacoeconomics. 2002;20 Suppl 3:11-29
references.pmid: 12457422
references.citation: J Health Econ. 2011 Mar;30(2):355-72
references.pmid: 21345506
references.citation: Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):267-75
references.pmid: 15386704
references.citation: J Child Adolesc Psychopharmacol. 1998;8(2):99-105
references.pmid: 9730075
references.citation: Pediatrics. 2003 Feb;111(2):237-43
references.pmid: 12563045
references.citation: Health Aff (Millwood). 2002 Jul-Dec;Suppl Web Exclusives:W408-19
references.pmid: 12703602
references.citation: Pediatrics. 1996 Dec;98(6 Pt 1):1084-8
references.pmid: 8951257
references.citation: Am J Public Health. 1999 Sep;89(9):1359-64
references.pmid: 10474553
references.citation: Arch Gen Psychiatry. 2005 Apr;62(4):435-41
references.pmid: 15809411
references.citation: J Am Acad Child Adolesc Psychiatry. 1996 Aug;35(8):978-87
references.pmid: 8755794
references.citation: J Manag Care Pharm. 2004 Mar-Apr;10(2):122-9
references.pmid: 15032561
references.citation: JAMA. 2000 Feb 23;283(8):1025-30
references.pmid: 10697062
references.citation: J Abnorm Child Psychol. 1992 Apr;20(2):213-32
references.pmid: 1593027
references.citation: J Manag Care Pharm. 2003 Mar-Apr;9(2):123-33
references.pmid: 14613341
references.citation: Curr Med Res Opin. 2010 Apr;26(4):977-89
references.pmid: 20178404
references.citation: Pharmacoeconomics. 2004;22(2 Suppl 2):1-14
references.pmid: 15660473
references.citation: J Abnorm Child Psychol. 1991 Oct;19(5):537-52
references.pmid: 1770184
references.citation: Curr Med Res Opin. 2011;27 Suppl 2:53-62
references.pmid: 21973231
references.citation: Med Care. 2003 Mar;41(3):398-406
references.pmid: 12618643
references.citation: N Engl J Med. 2003 Dec 4;349(23):2224-32
references.pmid: 14657430
references.citation: Pharmacoeconomics. 1996;10 Suppl 2:110-23
references.pmid: 10163428